Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Deng, Shiwei ^a   Yan, Tiandong ^a   Jendrny, Cathleen ^a   Nemecek, Andrea ^a   Vincetic, Mladen ^a   Gödtel Armbrust, Ute ^a   Wojnowski, Leszek ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOUBLE STRANDED DNA; DOXORUBICIN; ICRF 161; ISOENZYME; MUTANT PROTEIN; PIPERAZINEDIONE; RAZOXANE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; GYRASE INHIBITOR; PROTECTIVE AGENT; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG BINDING SITE; EMBRYO; ENZYME INHIBITION; ENZYME STABILITY; HEART PROTECTION; HUMAN; HUMAN CELL; IRON CHELATION; LUNG CANCER; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; BINDING SITE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEART; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM; MUTATION; PROTEIN DOMAIN; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; DEXRAZOXANE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; HEART; HUMANS; ISOENZYMES; MICE; MUTATION; MYOCARDIUM; MYOCYTES, CARDIAC; PROTECTIVE AGENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; TOPOISOMERASE II INHIBITORS;

EID: 84965095096     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-842     Document Type: Article

References (37)

1. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, the Childhood Cancer Survivor S: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
2. van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005, 1:CD003917.
3. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
4. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL: Dexrazoxaneassociated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007, 25:493-500.
5. van Dalen EC, van den Berg H, Raphael MF, Caron HN, Kremer LC: Should anthracyclines and dexrazoxane be used for children with cancer? Lancet Oncol 2011, 12:12-13.
6. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997, 15:1333-1340.
7. Hasinoff BB, Schroeder PE, Patel D: The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 2003, 64:670-678.
8. Schroeder PE, Patel D, Hasinoff BB: The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metab Dispos 2008, 36:1780-1785.
9. Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr, Ferrans VJ: Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol 1997, 40:400-408.
10. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
11. van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, 2:CD003917.
12. Hasinoff BB, Patel D, Wu X: The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003, 35:1469-1479.
13. Popelova O, Sterba M, Simunek T, Mazurova Y, Guncova I, Hroch M, Adamcova M, Gersl V: Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther 2008, 326:259-269.
14. Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L: Topoisomerase II(alpha)-dependent and-independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 2009, 8:1075-1085.
15. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF: Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007, 67:8839-8846.
16. Isik S, Sano K, Tsutsui K, Seki M, Enomoto T, Saitoh H, Tsutsui K: The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1). FEBS Lett 2003, 546:374-378.
17. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
18. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F: Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992, 1132:43-48.
19. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT: Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008, 105:9053-9058.
20. Carpenter AJ, Porter AC: Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell 2004, 15:5700-5711.
21. Mandraju RK, Kannapiran P, Kondapi AK: Distinct roles of Topoisomerase II isoforms: DNA damage accelerating alpha, double strand break repair promoting beta. Arch Biochem Biophys 2008, 470:27-34.
22. Linka RM, Porter AC, Volkov A, Mielke C, Boege F, Christensen MO: C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res 2007, 35:3810-3822.
23. Brawand D, Soumillon M, Necsulea A, Julien P, Csardi G, Harrigan P, Weier M, Liechti A, Aximu-Petri A, Kircher M, Albert FW, Zeller U, Khaitovich P, Grutzner F, Bergmann S, Nielsen R, Paabo S, Kaessmann H: The evolution of gene expression levels in mammalian organs. Nature 2011, 478:343-348.
24. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012, 7:562-578.
25. Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjornelund J, Sehested M, Jensen LH: Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009, 255:72-79.
26. Classen S, Olland S, Berger JM: Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003, 100:10629-10634.
27. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB: Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 1998, 58:1460-1468.
28. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M: Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res 1999, 59:3442-3450.
29. Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, Jensen PB, Sehested M: Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Lett 2002, 520:161-166.
30. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, Jensen PB: N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance. FEBS Lett 2000, 480:201-207.
31. Patel S, Jazrawi E, Creighton AM, Austin CA, Fisher LM: Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. Mol Pharmacol 2000, 58:560-568.
32. Herman EH, Ferrans VJ: Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 1993, 32:445-449.
33. van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, 6:CD003917.
34. Bonnefoi HR: Anthracyclines, HER2, and TOP2A: the verdict. Lancet Oncol 2011, 12:1084-1085.
35. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996, 73:1518-1524.
36. Withoff S, van der Zee AG, de Jong S, Hollema H, Smit EF, Mulder NH, de Vries EG: DNA topoisomerase IIalpha and-beta expression in human ovarian cancer. Br J Cancer 1999, 79:748-753.
37. Juenke JM, Holden JA: The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1993, 1216:191-196.